ALS Drug Development: Reflections from the Past and a Way Forward

60Citations
Citations of this article
58Readers
Mendeley users who have this article in their library.

Abstract

Tremendous advances in our understanding of pathogenesis of amyotrophic lateral sclerosis (ALS) have provided a rich pipeline of drugs for clinical trialists. At least 32 unique compounds have been tested. Nevertheless, riluzole is currently the only treatment that prolongs survival. We present a critical overview of past clinical trials, how therapies are selected for testing in people, challenges with ALS clinical trial design and conduct, and ways to best move forward. © 2008.

Cite

CITATION STYLE

APA

Aggarwal, S., & Cudkowicz, M. (2008). ALS Drug Development: Reflections from the Past and a Way Forward. Neurotherapeutics, 5(4), 516–527. https://doi.org/10.1016/j.nurt.2008.08.002

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free